Table of Content

1 Definition
1.1 Inclusion and Exclusion Criteria

2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Constrained Peptides: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Markets Overview
4.1 Introduction
4.1.1 Structure and Design of Constrained Peptides
4.1.2 Types of Constrained Peptides
4.2 Evolution of Constrained Peptides
4.3 Development of Constrained Peptides as Drugs
4.4 Global Constrained Peptide Drugs Market and Growth Potential, $Million, 2023-2031

5 Characteristics of Conformationally Constrained Peptides
5.1 Properties of Conformationally Constrained peptides
5.2 Synthesis of Constrained Peptides
5.2.1 Chemical Peptide Ligation and Bridging
5.2.2 Chemical Linkage of Peptides onto Scaffolds (CLIPS)
5.2.3 Peptide Stapling
5.2.4 Peptide Discovery Platform System (PDPS)
5.2.5 Liquid Phase Peptide Synthesis (LPPS)
5.2.6 Solid Phase Peptide Synthesis (SPPS)
5.3 Advances in Peptide Technology
5.4 Peptide Display and Selection System

6 Pipeline
6.1 Constrained Peptide Drugs Pipeline Analysis
6.2 Constrained Peptide Drugs Clinical Trial Design
6.2.1 Zilucoplan (RA101495)
6.2.1.1 Product Profile
6.2.1.2 Zilucoplan (RA101495) Phase III Study Design
6.2.1.3 Zilucoplan Efficacy, Safety, and Tolerability (Phase II)
6.2.1.4 Zilucoplan Pharmacokinetics and Pharmacodynamics Profile (Phase I)
6.2.2 BT1718
6.2.2.1 Product Profile
6.2.2.2 BT1718 Preclinical Studies
6.2.2.3 BT1718 Phase I/IIa Clinical Study Design
6.2.3 BT5528
6.2.3.1 Product Profile
6.2.3.2 BT5528 Preclinical Studies
6.2.3.3 BT5528 Phase I/II Clinical Study Design
6.2.4 Rusfertide (PTG-300)
6.2.4.1 Product Profile
6.2.4.2 Rusfertide (PTG-300) Ongoing Phase II Clinical Study Design
6.2.4.3 Rusfertide (PTG-300) Clinical Development Program in Hereditary Hemochromatosis (HH)
6.2.5 PN-943
6.2.5.1 Product Profile
6.2.5.2 PN-943 Preclinical Proof-of-Concept Studies
6.2.5.3 PN-943 Phase I Clinical Trial Design
6.2.5.4 PN-943 Phase II Ideal Clinical Study Design in Ulcerative Colitis

7 Impact of COVID-19 on Global Constrained Peptide Drugs Market
7.1 Impact on Constrained Peptide Drugs Companies
7.2 Clinical Trial Disruptions and Resumptions

8 Industry Insights
8.1 Overview
8.2 Challenges in Constrained Peptides Regulatory Approval Pathway
8.3 Regulatory Scenario of Constrained Peptides
8.4 Legal Requirements and Frameworks in the U.S.
8.4.1 Clinical Trial Authorization
8.4.2 Marketing Authorization
8.4.3 U.S. FDA Guidelines for NDA Submission
8.4.4 Post-Authorization Regulations
8.5 Legal Requirements and Frameworks in Europe
8.5.1 EMA Drug License Application Process
8.5.2 Centralized Procedure
8.5.3 Decentralized Procedure
8.5.4 Mutual-Recognition Procedure
8.5.5 National Procedure
8.6 Legal Requirements and Frameworks in Asia-Pacific
8.6.1 Legal Requirements and Frameworks in Japan

9 Market Dynamics
9.1 Impact Analysis
9.2 Market Drivers
9.2.1 Enhanced Binding Affinity and Cellular Uptake
9.2.2 Development of Synthetic Constraining Methods
9.2.3 Limitations with Conventional Peptides
9.2.4 Increasing Government and Private Funding
9.2.4.1 Funding by Private Companies
9.2.4.2 Funding by Public Companies
9.2.4.3 Funding by Government Institutions
9.3 Market Restraints
9.3.1 Increased Competition from Biologics
9.3.2 Risk of Immunogenic Effects and Unsatisfactory ADME Properties
9.4 Market Opportunities
9.4.1 Role of Constrained Peptides in Drug Discovery
9.4.2 Various Application in CNS Disease Studies and Anti-Cancer Therapy

10 Market Analysis
10.1 Global Constrained Peptide Drugs Market (by Peptide Type), $Million, 2023-2031
10.1.1 Overview
10.1.2 Cyclic Peptides
10.1.3 Disulfide-Rich Peptides (DRPs)
10.2 Global Constrained Peptide Drugs Market (by Product), $Million, 2023-2031
10.2.1 Overview
10.2.2 BT1718
10.2.3 BT5528
10.2.4 Zilucoplan (RA101495)
10.2.5 Rusfertide (PTG-300)
10.2.6 PN-943
10.3 Global Constrained Peptide Drugs Market (by Country), $Million, 2023-2031
10.3.1 North America
10.3.1.1 U.S.
10.3.1.2 Canada
10.3.2 Europe
10.3.2.1 U.K.
10.3.2.2 Germany
10.3.2.3 France
10.3.2.4 Italy
10.3.2.5 Spain
10.3.3 Asia-Pacific
10.3.3.1 Japan

11 Markets - Competitive Benchmarking & Company Profiles
11.1 Competitive Landscape
11.1.1 Key Developments
11.1.2 Regulatory and Legal Activities
11.1.3 Mergers and Acquisitions
11.1.4 Synergistic Activities
11.1.5 Funding Activities
11.1.6 Clinical Developments
11.2 Company Profiles
11.2.1 Overview
11.3 Aileron Therapeutics, Inc
11.3.1 Company Overview
11.3.2 Role of Aileron Therapeutics, Inc in the Global Constrained Peptide Drugs Market
11.3.3 R&D Analysis
11.3.4 SWOT Analysis
11.4 Bicycle Therapeutics, PLC
11.4.1 Company Overview
11.4.2 Role of Bicycle Therapeutics, PLC in the Global Constrained Peptide Drugs Market
11.4.3 Collaboration with Biopharmaceutical Companies
11.4.4 R&D Analysis
11.4.5 SWOT Analysis
11.5 Polyphor Limited
11.5.1 Company Overview
11.5.2 Role of Polyphor Limited in the Global Constrained Peptide Drugs Market
11.5.3 Collaboration with Research Institutions and Biopharmaceutical Companies
11.5.4 Financials
11.5.5 R&D Analysis
11.5.6 SWOT Analysis
11.6 Protagonist Therapeutics, Inc
11.6.1 Company Overview
11.6.2 Role of Protagonist Therapeutics, Inc in the Global Constrained Peptide Drugs Market
11.6.3 Collaboration with Biopharmaceutical Companies
11.6.4 Financials
11.6.5 R&D Analysis
11.6.6 SWOT Analysis
11.7 Santhera Pharmaceuticals Holding
11.7.1 Company Overview
11.7.2 Role of Santhera Pharmaceuticals Holding in the Global Constrained Peptide Drugs Market
11.7.3 Financials
11.7.4 SWOT Analysis
11.8 Union Chimique Belge S.A. (UCB)
11.8.1 Company Overview
11.8.2 Role of Union Chimique Belge S.A. in the Global Constrained Peptide Drugs Market
11.8.3 Financials
11.8.4 R&D Analysis
11.8.5 SWOT Analysis
11.9 Pepscan Therapeutics B.V.
11.9.1 Company Overview
11.9.2 Role of Pepscan Therapeutics B.V. in the Global Constrained Peptide Drugs Market
11.1 Pepticom Ltd.
11.10.1 Company Overview
11.10.2 Role of Pepticom Ltd. in the Global Constrained Peptide Drugs Market
11.11 PeptiDream, Inc.
11.11.1 Company Overview
11.11.2 Role of PeptiDream, Inc. in the Global Constrained Peptide Drugs Market
11.12 CPC Scientific Inc.
11.12.1 Company Overview
11.12.2 Role of CPC Scientific Inc. in the Global Constrained Peptide Drugs Market
11.13 Creative Peptides
11.13.1 Company Overview
11.13.2 Role of Creative Peptides in the Global Constrained Peptide Drugs Market
11.14 Bio-Synthesis Inc
11.14.1 Company Overview
11.14.2 Role of Bio-Synthesis Inc in the Global Constrained Peptide Drugs Market
List of Figures
Figure 1: Peptide-Based Drugs Approved by the U.S. FDA (2015-2019)
Figure 2: Constrained Peptide Drugs Global Clinical Trials (by Phase), 2021
Figure 3: Constrained Peptide Drugs Global Clinical Trial (by Indication), 2021
Figure 4: Global Constrained Peptide Drugs Market Growth Revenue, $Million, 2023-2031
Figure 5: Global Constrained Peptide Drugs: Impact Analysis
Figure 6: Revenue Contribution of Different Segments, 2023, 2025, and 2031
Figure 7: Global Constrained Peptide Drugs Market (by Product)
Figure 8: Global Constrained Peptide Drugs Market (by Region), $Million, 2023-2031
Figure 9: Global Constrained Peptide Drugs Market Segmentation
Figure 10: Global Constrained Peptide Drugs Methodology
Figure 11: Primary Research Methodology
Figure 12: Epidemiology-Based Approach
Figure 13: Inducing Conformational Effects
Figure 14: Two Main Types of Constraints
Figure 15: Methodology for Restricting Conformation in Peptides
Figure 16: Types of Constrained Peptides
Figure 17: Key Milestones in Evolution of Constrained Peptides
Figure 18: Major Factors Affecting Constrained Peptide Development
Figure 19: Peptide-Based Drugs Approved by the U.S. FDA (2015-2019)
Figure 20: Global Constrained Peptide Drugs Market Growth Revenue, $Million, 2023-2031
Figure 21: Synthesis of Constrained Peptides using Chemical Peptide Ligation and Bridging
Figure 22: Constrained Peptide Synthesis using CLIPS Technology
Figure 23: Constrained Peptides Synthesis using Peptide Stapling
Figure 24: Peptide Discovery Platform System (PDPS) Technology
Figure 25: Synthesis of Peptides Using Liquid Phase Peptide Synthesis
Figure 26: Synthesis of Peptides Using Solid Phase Peptide Synthesis
Figure 27: Companies and Their Proprietary Technologies
Figure 28: Phage Display Technology
Figure 29: Constrained Peptide Drugs Global Clinical Trials (by Phase), 2021
Figure 30: Constrained Peptide Drugs Global Clinical Trials (by Indication), 2021
Figure 31: Zilucoplan (RA101495) Mechanism of Action
Figure 32: Zilucoplan Phase III Clinical Trial Design for Generalized Myasthenia Gravis
Figure 33: Zilucoplan Phase II Clinical Trial Design for Generalized Myasthenia Gravis
Figure 34: Zilucoplan Safety and Efficacy Tolerability Profile
Figure 35: Zilucoplan PK/PD Profile Results
Figure 36: Illustration of BT1718
Figure 37: High MT1-MMP Expressing Tumors Examples
Figure 38: BT1718 Preclinical Studies Framework
Figure 39: BT1718 Phase I Portion Clinical Study
Figure 40: BT1718 Phase IIa Portion Clinical Study
Figure 41: Illustration of BT5528
Figure 42: Tumors with EphA2 overexpression
Figure 43: BT5528 Preclinical Studies Framework
Figure 44: BT5528 Phase I Portion Clinical Study
Figure 45: Limited Current Treatment Options in Polycythemia Vera
Figure 46: Rusfertide (PTG-300) Phase II clinical Design for Polycythemia Vera
Figure 47: Clinical Proof-of-Concept Study Intervention Model Design
Figure 48: Updated Results from Ongoing Phase II Clinical Study
Figure 49: Clinical Proof-of-Concept Study Intervention Model Design for HH
Figure 50: Results from PN-943 Phase I Clinical Trial
Figure 51: PN-943 Phase II Ongoing Clinical Study Design
Figure 52: PN-943 Phase II IDEAL Study Intervention Model Design
Figure 53: Clinical Trial Authorization for Constrained Peptides in the U.S.
Figure 54: Steps for Obtaining Marketing Authorization
Figure 55: U.S. FDA Review Timeline
Figure 56: EMA Review Timeline
Figure 57: Factors Affecting Constrained Peptide Cellular Penetration
Figure 58: Key Innovative Modern Technologies and Constraining Methods
Figure 59: Properties of Traditional Peptides Vs. Constrained Peptides
Figure 60: Revenue Contribution of Different Segments, 2023, 2025, and 2031
Figure 61: Global Constrained Peptide Drugs Market (Cyclic Peptides), $Million, 2023-2031
Figure 62: Global Constrained Peptide Drugs Market (Disulfide-Rich Peptides), $Million, 2025-2031
Figure 63: Global Constrained Peptide Drugs Market (by Product)
Figure 64: Global Revenue for BT1718, $Million, 2025-2031
Figure 65: Global Revenue for BT5528, $Million, 2027-2031
Figure 66: Global Revenue for Zilucoplan (RA101495), $Million, 2023-2031
Figure 67: Global Revenue for Rusfertide (PTG-300), $Million, 2025-2031
Figure 68: Global Revenue for PN-943, $Million, 2026-2031
Figure 69: Global Constrained Peptide Drugs Market (by Region)
Figure 70: Global Constrained Peptide Drugs Market (by Region), $Million, 2023-2031
Figure 71: North America Constrained Peptide Drugs Market, $Million, 2023-2031
Figure 72: North America: Market Dynamics
Figure 73: North America Constrained Peptide Drugs Market (by Country), $Million, 2023 and 2031
Figure 74: U.S. Constrained Peptide Drugs Market, $Million, 2023-2031
Figure 75: Canada Constrained Peptide Drugs Market, $Million, 2023-2031
Figure 76: Europe Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 77: Europe: Market Dynamics
Figure 78: Europe Constrained Peptide Drugs Market (by Country), $Million, 2025 and 2031
Figure 79: U.K. Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 80: Germany Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 81: France Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 82: Italy Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 83: Spain Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 84: Japan Constrained Peptide Drugs Market, $Million, 2025-2031
Figure 85: Share of Key Developments and Strategies, January 2018-July 2021
Figure 86: Share of Regulatory and Legal Activities (by Company), January 2018-July 2021
Figure 87: Share of Mergers and Acquisitions (by Company), January 2018-July 2021
Figure 88: Share of Synergistic Activities (by Company), January 2018-July 2021
Figure 89: Share of Funding Activities (by Company), January 2018-July 2021
Figure 90: Share of Clinical developments (by Company), January 2018-July 2021
Figure 91: Aileron Therapeutics, Inc: Product Portfolio
Figure 92: Aileron Therapeutics, Inc: Overall R&D Expenditure, 2019-2020
Figure 93: Aileron Therapeutics, Inc: SWOT Analysis
Figure 94: Bicycle Therapeutics, PLC: Product Portfolio
Figure 95: Bicycle Therapeutics, PLC Collaboration with Biopharmaceutical Companies
Figure 96: Bicycle Therapeutics, PLC: Overall R&D Expenditure, 2018-2020
Figure 97: Bicycle Therapeutics, PLC: SWOT Analysis
Figure 98: Polyphor Limited: Product Portfolio
Figure 99: Polyphor Limited Collaboration with Research Institutions and Biopharmaceutical Companies
Figure 100: Polyphor Limited: Overall Financials, 2018-2020
Figure 101: Polyphor Limited: Revenue (by Region), 2018-2020
Figure 102: Polyphor Limited: Overall R&D Expenditure, 2018-2020
Figure 103: Polyphor Limited: SWOT Analysis
Figure 104: Protagonist Therapeutics, Inc: Product Portfolio
Figure 105: Protagonist Therapeutics, Inc Collaboration with Biopharmaceutical Companies
Figure 106: Protagonist Therapeutics, Inc: Overall Financials, 2018-2020
Figure 107: Protagonist Therapeutics, Inc: Overall R&D Expenditure, 2018-2020
Figure 108: Protagonist Therapeutics, Inc: Pipeline Products R&D Expenditure, 2018-2020
Figure 109: Protagonist Therapeutics, Inc: SWOT Analysis
Figure 110: Santhera Pharmaceuticals Holding: Product Portfolio
Figure 111: Santhera Pharmaceuticals Holding: Overall Financials, 2018-2020
Figure 112: Santhera Pharmaceuticals Holding: SWOT Analysis
Figure 113: Union Chimique Belge S.A.: Product Portfolio
Figure 114: Union Chimique Belge S.A.: Overall Financials, 2018-2020
Figure 115: Union Chimique Belge S.A.: Overall R&D Expenditure, 2018-2020
Figure 116: Union Chimique Belge S.A.: SWOT Analysis
List of Tables
Table 1: Properties of Conformationally Constrained Peptides
Table 2: Display and Selection System Employed by Companies
Table 3: Emerging Constrained Peptide Drugs Pipeline
Table 4: Zilucoplan Phase II Baseline Characteristics Results
Table 5: Selected Clinical Data Comparison between Zilucoplan and Soliris
Table 6: Pharmacokinetic Profile of BT1718
Table 7: Impact of COVID-19 on Constrained Peptide Drugs Companies
Table 8: Regulatory Scenario of Constrained Peptides
Table 9: Funding by Private Companies
Table 10: Bicycle Therapeutics, PLC: Overall Product Portfolio
Table 11: Protagonist Therapeutics, Inc: Overall Product Portfolio
Table 12: Pepscan Therapeutics B.V.: Product Portfolio
Table 13: Pepticom Ltd.: Product Portfolio
Table 14: PeptiDream, Inc.: Product Portfolio
Table 15: CPC Scientific Inc.: Product Portfolio
Table 16: Figure: Creative Peptides: Product Portfolio
Table 17: Bio-Synthesis Inc: Product Portfolio